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Abstract
The first prospective population-based study to
examine risk of erectile dysfunction in men with gout
in the western world has been published. It reports
that following their first diagnosis of gout, men have a
31% higher risk of erectile dysfunction than matched
controls, although the absolute increase in risk is
small. Of interest, the incidence of erectile dysfunction
reported in this study is tenfold higher than those
reported in nation-wide cohort studies from Taiwan.
There is a need for further prospective cohort studies
to examine the possible mechanistic association
between gout, hyperuricaemia and erectile
dysfunction.
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The primary care-based prospective cohort study by
Abdul Sultan et al. [1] using data from the UK’s Clinical
Practice Research Datalink (CPRD) reports that follo-
wing their first diagnosis of gout, men have a 31% higher
risk of erectile dysfunction (ED) than matched controls,
although the absolute increase in risk is small (e.g. 0.6%
for a new consultation for ED, and 0.3% for receiving a
prescription), reflecting a limited attributable effect on
ED compared to other factors.
The authors are to be congratulated for undertaking
this first prospective population-based study to examine
risk of ED in men with gout in the western world. Only
three other studies have examined ED in men with gout.
One small hospital-based USA study surveyed people
attending rheumatology clinics and reported that 76% of
people with gout (n = 81) had ED compared to 51% of
non-gout controls (n = 115) [2]. Interestingly, the
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incidence rate of ED reported in this CPRD study is
tenfold higher than those reported in two nation-wide
cohort studies using the National Health Insurance Re-
search Database (NHIRD) in Taiwan [3, 4]. It is possible
that this difference results from cultural reasons or lack
of health insurance cover for ED in Taiwan [1]. However,
hazard ratios for ED in those with gout in the Taiwan
studies were comparable to the current study [1, 3, 4].
Given the prospective study design and source of
recruitment we feel that this study provides reasonable
estimates of rates of ED in men with gout in the western
world [1], though the real prevalence is likely to be
higher because many men may not consult their GP
about it. Due to data limitations, the authors could not
classify ED according to cause. However, data from the
NHIRD showed a greater risk of incident organic ED
than psychogenic ED in men with gout compared to
men without gout (odds ratio (95% confidence interval)
1.52(1.03–2.22) vs. 1.18(1.03–1.35), respectively) [4],
which suggests an important role for hyperuricaemia in
causing vasculopathy and subsequent ED.
Abdul Sultan et al. [1] performed stratified and multi-
variate analyses to account for several confounders that
may associate with gout and ED, and used landmark ana-
lysis to account for survivor bias. Interestingly, they found
an elevated risk of ED prior to gout diagnosis, which
suggests that ED may result from hyperuricaemia which
precedes gout by some years [5]. However, the elevated
risk for ED was restricted just to the 1-year period prior to
gout diagnosis [1]. This suggests a possible delay between
symptom onset and first consultation for gout, or that
Read codes for gout are not applied at initial GP consulta-
tions, potentially due to diagnostic uncertainty in early
stages of illness [6]. However, the control group for the
analysis of association between prior diagnosis of ED and
subsequent coding for gout was not selected according to
the serum uric acid (SUA) and may have undetected
hyperuricaemia, thereby minimizing the association.
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Interestingly, a previous CPRD study identified an
increased risk of many comorbidities that may relate
to chronic hyperuricaemia (including cardiovascular
diseases and depression) in up to 10 years prior to
initial gout diagnosis and a subsequent increased risk
of the same comorbidities in the 5 years following
diagnosis [7]. Depression was identified as an associ-
ation with incident and subsequent gout in the
current study and could have contributed to an in-
crease in psychogenic ED. Thus, there is a need for
further prospective cohort studies to examine the
possible mechanistic association between hyperuricae-
mia and ED. Given that screening for hyperuricaemia
is not standard clinical practice in the UK, such stud-
ies cannot be conducted using UK primary care data.
This study found no protective effect of urate lowering
treatment (ULT) on the incidence of ED. This is not un-
expected as most people with gout in the UK who re-
ceive ULT are on suboptimal doses and do not achieve
target SUAs of <6 mg/dl [8]. Of interest, the authors
found a trend towards higher risk of ED in those treated
with ULT, although this was not statistically significant.
This may be due to residual confounding by indication,
as individuals with more severe disease and comorbidi-
ties are more likely to receive ULT. Such confounding
could have been minimized by propensity score match-
ing or adjustment. Thus, we feel that the lack of risk re-
duction for incident ED by ULT should not be
interpreted as failure of ULT in preventing ED, since the
suboptimal dosing of allopurinol in the UK is unlikely to
exert any beneficial effect on vascular health, or indeed
mortality [8, 9].
In summary, health care professionals should be aware
that men with gout are at higher risk of ED, and might
enquire about this during consultations. Further studies
are required to determine whether the association be-
tween gout and ED is due to hyperuricaemia, or if gout
confers a higher risk of ED than hyperuricaemia alone.
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